R&D

Research Institute

Holzapfel Microbiome
Research Institute

HEM Pharma established its research institute based on the research philosophy and expertise of the globally renowned microbiologist, Professor Wilhelm H.Holzapfel. Professor Holzapfel has made groundbreaking achievements in the field of microbiology, earning recognition for his academic authority. He previously served as the Director of the German Federal Max Rubner Institute and as the President of the International Commission on Food Microbiology and Hygiene (ICFMH of IUMS). As a testament to his scientific contributions, a newly discovered microbial genus, Holzapfelia (Type species: Holzapfelia floricola), has been named in his honor and registered in the academic community. Professor Holzapfel contributed to the establishment of the research institute and the initial direction setting. To this day, he continues to play a pivotal role in positioning HEM Pharma at the forefront of global microbiome research and development.

The Holzapfel Microbiome Research Institute leads innovative microbiome research and technological advancements by integrating data-driven analysis with cutting-edge AI technologies and utilizing comprehensive data for research and development.

Bioinformatics Center
  • Statistical analysis of bioinformation data, machine learning, research on deep learning
  • Development of customized microbiome service technology through data management and utilization
  • Development of a personalized healthcare app platform utilizing generative AI
  • Utilizing clinical data such as research data, and artificial intelligence algorithms optimized for new drug development
Multi-Omics Center
  • Conducting research and technology development from personalized experiments and analyses
  • Screening and analysis for providing personalized probiotic solutions, discovering new markers
  • Discovering metabolome-based biomarkers for various diseases and healing and conducting research on mechanisms
  • Genome-based intestinal microbiota analysis
Research Planning
  • Supporting R&D-related activities
  • Establishing an overall portfolio and technology roadmap for research, production, and business
  • Execution of national projects through industry-academic collaboration and establishment of patent strategies
  • Planning of customized microbiome services
  • Development of microbiome therapeutics utilizing platforms such as the LBP Discovery Platform